<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344614</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-311</org_study_id>
    <nct_id>NCT03344614</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>An Open Single Arm Exploratory Study of Apatinib Mesylate Tablets in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      30 patients with advanced colorectal cancer will be enrolled to observe the efficacy and
      safety of raltitrexed combined with apatinib as a third-line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we plan to enroll 30 patients with advanced colorectal cancer after failure of
      second-line standard chemotherapy. The therapeutic regimen is raltitrexed, 3 mg/㎡, ivgtt, d1,
      apatinib 500 mg, qd,po, d1-21, Every 3 weeks for 1 cycles, the primary end point was PFS, the
      secondary end point was OS, DCR, ORR etc. Aim to observe the efficacy and safety of
      raltitrexed combined with apatinib as a third-line treatment of in patients with advanced
      colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free survival progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>12 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>12 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>raltitrexed combined with apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltitrexed combined with apatinib</intervention_name>
    <description>raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles</description>
    <arm_group_label>raltitrexed combined with apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Male or female, ≥ 18 of age;

          -  2.Histological confirmed advanced colorectal adenocarcinoma，and at least one
             measurable lesion;

          -  3.Have failed for ≥ 2 lines of standard chemotherapy(included Fluorouracil, irinotecan
             and oxaliplatin);

          -  4.ECOG performance status 0-2;

          -  5.Life expectancy of more than 3 months;

          -  6.The main organs function is well, and randomized within 14 days before the relevant
             inspection indicators to meet the following requirements:

               1. blood routine test Hgb ﹥90g/L, ANC﹥1.5×109/L, Platelets ﹥ 100×109/L,

               2. biochemical tests Serum Total bilirubin ≤ 1.5 X UNL(upper normal limit), ALT or
                  AST ≤ 2 xUNL, and ﹤ 5 x UNL（Hematogenous metastases）, Creatinine clearance rate≥
                  60 ml/min(Cockcroft-Gault formula),

               3. Doppler echocardiography assessment：LVEF ≥ 50%;

          -  7.No serious heart, lung, liver, kidney dysfunction; no jaundice and gastrointestinal
             obstruction; no acute infection;

          -  8.Signed informed consent;

          -  9.Good compliance, and family members agree to receive survival follow-up.

        Exclusion Criteria:

          -  1.Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiyan Si, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital (301 Military Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiyan Si, M.D.</last_name>
    <phone>+8613911070673</phone>
    <email>sihaiyan2008@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guanghai Dai, M.D.</last_name>
    <phone>+8613801232381</phone>
    <email>daigh301@vip.sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital (301 Military Hospital)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Si, M.D.</last_name>
      <phone>+8613911070673</phone>
      <email>sihaiyan2008@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Dai, Guanghai</investigator_full_name>
    <investigator_title>Department Director,M.D.</investigator_title>
  </responsible_party>
  <keyword>third-line treatment</keyword>
  <keyword>apatinib</keyword>
  <keyword>raltitrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

